Shanghai Junshi Biosciences Future Growth
Future criteria checks 2/6
Shanghai Junshi Biosciences is forecast to grow earnings and revenue by 41.3% and 23.1% per annum respectively. EPS is expected to grow by 41.3% per annum. Return on equity is forecast to be -22.2% in 3 years.
Key information
41.3%
Earnings growth rate
41.3%
EPS growth rate
Biotechs earnings growth | 35.4% |
Revenue growth rate | 23.1% |
Future return on equity | -22.2% |
Analyst coverage | Low |
Last updated | 05 Apr 2024 |
Recent future growth updates
Recent updates
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?
Mar 22Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%
Jan 26Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Dec 17Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?
Nov 20Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?
Sep 05Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
May 22Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate
May 01A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jan 16Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 03Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?
Oct 12A Look At The Fair Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Jul 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,278 | -631 | -461 | -1,147 | 3 |
12/31/2025 | 2,623 | -1,009 | -984 | -1,431 | 4 |
12/31/2024 | 1,685 | -1,712 | -2,460 | -1,953 | 2 |
12/31/2023 | 1,503 | -2,283 | -2,838 | -2,005 | N/A |
9/30/2023 | 1,222 | -2,200 | -3,037 | -2,323 | N/A |
6/30/2023 | 1,177 | -2,473 | -2,988 | -2,544 | N/A |
3/31/2023 | 1,079 | -2,535 | -3,489 | -3,067 | N/A |
12/31/2022 | 1,453 | -2,388 | -2,170 | -1,776 | N/A |
9/30/2022 | 2,525 | -1,924 | -1,708 | -1,182 | N/A |
6/30/2022 | 2,856 | -1,643 | -1,663 | -1,109 | N/A |
3/31/2022 | 3,039 | -1,495 | -1,207 | -434 | N/A |
12/31/2021 | 4,025 | -721 | -1,507 | -605 | N/A |
9/30/2021 | 3,302 | -945 | -1,769 | -902 | N/A |
6/30/2021 | 3,134 | -1,060 | -1,735 | -892 | N/A |
3/31/2021 | 3,038 | -1,062 | -1,398 | -703 | N/A |
12/31/2020 | 1,595 | -1,669 | -2,037 | -1,456 | N/A |
9/30/2020 | 1,259 | -1,418 | -1,945 | -1,365 | N/A |
6/30/2020 | 1,041 | -1,056 | -1,699 | -1,032 | N/A |
3/31/2020 | 868 | -600 | -1,876 | -1,120 | N/A |
12/31/2019 | 775 | -747 | -2,042 | -1,179 | N/A |
9/30/2019 | 528 | -732 | -1,927 | -1,092 | N/A |
6/30/2019 | 310 | -735 | -1,704 | -913 | N/A |
3/31/2019 | 79 | -992 | -1,555 | -824 | N/A |
12/31/2018 | 1 | -717 | -1,060 | -511 | N/A |
9/30/2018 | N/A | -516 | -877 | -387 | N/A |
6/30/2018 | N/A | -439 | -775 | -443 | N/A |
3/31/2018 | 0 | -347 | -603 | -364 | N/A |
12/31/2017 | 1 | -321 | -611 | -347 | N/A |
9/30/2017 | 9 | -279 | N/A | -348 | N/A |
6/30/2017 | 5 | -246 | N/A | -275 | N/A |
3/31/2017 | 9 | -191 | N/A | -243 | N/A |
12/31/2016 | 4 | -131 | N/A | -185 | N/A |
9/30/2016 | 4 | -109 | N/A | -169 | N/A |
6/30/2016 | 2 | -83 | N/A | -139 | N/A |
3/31/2016 | 2 | -71 | N/A | -110 | N/A |
12/31/2015 | 3 | -58 | N/A | -82 | N/A |
9/30/2015 | 5 | -43 | N/A | -66 | N/A |
6/30/2015 | 7 | -27 | N/A | -50 | N/A |
3/31/2015 | 6 | -26 | N/A | -45 | N/A |
12/31/2014 | 6 | -25 | N/A | -39 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1877 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1877 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1877 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1877's revenue (23.1% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
High Growth Revenue: 1877's revenue (23.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1877 is forecast to be unprofitable in 3 years.